北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 血液科  > 期刊论文
学科主题: 临床医学
题名:
Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia
作者: Jiang, Hao1; Liang, Gong-wen2; Huang, Xiao-jun1; Jiang, Qian1; Han, Sheng2; Shi, Lu-wen2; Zhu, Hong-hu1
关键词: Acute promyelocytic leukemia ; Medical costs ; Arsenic ; Retinoic acid
刊名: LEUKEMIA RESEARCH
发表日期: 2015-12-01
DOI: 10.1016/j.leukres.2015.09.007
卷: 39, 期:12, 页:1319-1324
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology ; Hematology
研究领域[WOS]: Oncology ; Hematology
关键词[WOS]: ACUTE MYELOID-LEUKEMIA ; TRANS-RETINOIC ACID ; REMISSION INDUCTION ; TETRA-SULFIDE ; TRIOXIDE ; THERAPY ; DIFFERENTIATION ; CHEMOTHERAPY
英文摘要:

We have demonstrated that oral arsenic (Realgar-Indigo naturalis formula, RIF) plus all-trans retinoic acid (ATRA) is not inferior to intravenous arsenic trioxide (ATO) plus ATRA as the first-line treatment of acute promyelocytic leukemia (APL). To compare the cost-effectiveness of oral and intravenous arsenic, we analyzed the results of 30 patients in each group involved in a randomized controlled trial at our center. The median total medical costs were $13,183.49 in the RIF group compared with $24136.98 in the ATO group (p <0.0001). This difference primarily resulted from the different costs of induction therapy (p = 0.016) and maintenance treatment (p < 0.0001). The length of hospitalization for the RIF group was significantly lower than that for the ATO group (24 vs. 31 days, p <0.0001) during induction therapy. During maintenance treatment, the estimated medical costs were $2047.14 for each patient in the RIF group treated at home compared with $11273.81 for each patient in the ATO group treated in an outpatient setting (p <0.0001). We conclude that oral RIF plus ATRA significantly reduced the medical costs and length of hospital stay during induction and remission therapy compared with ATO plus ATRA in APL patients. (C) 2015 Elsevier Ltd. All rights reserved.

语种: 英语
所属项目编号: 81370639 ; 81170483 ; Z111107067311070 ; Z141107002514004 ; Z141100000214011 ; 2012AA02A505
项目资助者: National Natural Science Foundation of China ; Beijing Municipal Science and Technology Commission ; National High-tech R&amp ; D Program (863 Program)
WOS记录号: WOS:000365335200003
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/54014
Appears in Collections:北京大学第二临床医学院_血液科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Peoples Hosp, Inst Hematol, Beijing 100044, Peoples R China
2.Peking Univ, Dept Pharm Adm & Clin Pharm, Hlth Sci Ctr, Beijing 100191, Peoples R China

Recommended Citation:
Jiang, Hao,Liang, Gong-wen,Huang, Xiao-jun,et al. Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia[J]. LEUKEMIA RESEARCH,2015,39(12):1319-1324.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Jiang, Hao]'s Articles
[Liang, Gong-wen]'s Articles
[Huang, Xiao-jun]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Jiang, Hao]‘s Articles
[Liang, Gong-wen]‘s Articles
[Huang, Xiao-jun]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace